BioSpace News Archive

On March 30, 2023, Viva Biotech Holdings (1873.HK) announced that during the year ended December 31, 2022 (the “Reporting Period”), the revenue of the Group increased to RMB2,379.6 million from RMB2,104.1 million for the corresponding period last year, representing a YoY increase of approximately 13.1%.

Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.

Comanche Biopharma Corp., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for Comanche’s novel, siRNA therapy to treat preeclampsia.

DXVX announces that its affiliated company Oxford Vacmedix has completed Phase 1a trial of cancer vaccine and plans to proceed Phase 1b trial of OVM-200.

Gandeeva Therapeutics, Inc. announced the initiation of a research collaboration with Moderna Inc. to explore applications of Gandeeva’s differentiated technology platform for a Moderna program.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the fiscal year ended December 31, 2022 and provided a business update.

European biotech AlgoTx, a clinical stage innovator in complex pain, announces that the U.S. Food and Drug Administration has cleared the Investigational New Drug Application for its Phase 2 first-in-class candidate ATX01 in the treatment of erythromelalgia.

FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer.

LimFlow SA announced that results from the PROMISE II U.S. pivotal trial were published.

Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 27.